Celgene Corp (CELG)

116.78
NASDAQ : Health Care
Prev Close 116.74
Day Low/High 116.34 / 117.18
52 Wk Low/High 94.42 / 127.64
Avg Volume 3.54M
Exchange NASDAQ
Shares Outstanding 780.82M
Market Cap 91.15B
EPS 2.60
P/E Ratio 43.89
Div & Yield N.A. (N.A)

Latest News

Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclerosis Treatment

Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclerosis Treatment

The trial enrolled 1,313 RMS patients in 21 countries for two years of study.

Celgene Announces Positive Results From RADIANCE, The Second Pivotal Phase III Trial Of Oral Ozanimod In Patients With Relapsing Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that its phase III RADIANCE trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with...

Broad Range Of Clinical Data Evaluating Celgene Therapies To Be Presented At American Society Of Clinical Oncology (ASCO)

Celgene Corporation (NASDAQ: CELG) today announced that data from a broad range of company-sponsored and investigator-initiated studies evaluating Celgene investigational agents and investigational uses of marketed products...

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract

The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.

Raytheon, Celgene, Orbital ATK, CenturyLink: 'Mad Money' Lightning Round

Raytheon, Celgene, Orbital ATK, CenturyLink: 'Mad Money' Lightning Round

Jim Cramer is bullish on Raytheon, Celgene, and Orbital ATK; he's bearish on CenturyLink and Pennsylvania Real Estate Investments.

It's Hard to Find Winners and Stick With Them: Cramer's 'Mad Money' Recap (Tuesday 5/16/17):

It's Hard to Find Winners and Stick With Them: Cramer's 'Mad Money' Recap (Tuesday 5/16/17):

Jim Cramer says Home Depot, AMD and Alphabet are three examples of winners that have been so hard to stay in that he think you can still buy.

Here Are Some of Congress' Favorite Stocks

Here Are Some of Congress' Favorite Stocks

While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

3 Post-Earnings Biotech Buys

3 Post-Earnings Biotech Buys

These names are now undervalued, despite solid results and good fundamentals.

Luspatercept Phase 2 Data Presented At The 14th International Symposium On Myelodysplastic Syndromes

Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ:CELG), today announced preliminary Phase 2 results from the ongoing three-month base and long-term extension studies with investigational drug luspatercept...

Celgene Stock Falls Following Argus Downgrade

Celgene Stock Falls Following Argus Downgrade

Celgene shares were down more than 2% Friday afternoon.

Earnings: Assessing 3 Biotech Bellwethers

Earnings: Assessing 3 Biotech Bellwethers

How did Celgene, AbbVie and Gilead fare last quarter?

Celgene Corporation To Webcast At Upcoming Investor Conferences

Celgene Corporation (NASDAQ:CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company.

Takeaways and Observations; What's Driving My Approach: Doug Kass' Views

Takeaways and Observations; What's Driving My Approach: Doug Kass' Views

Doug Kass shares his thoughts on Twitter, Apple and Alphabet.

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Celgene Has Loads of Potential

Celgene Has Loads of Potential

This stock is poised for more upside.

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.

Celgene Reports First Quarter 2017 Operating And Financial Results

Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,950 million for the first quarter of 2017, an 18 percent increase from the same period in 2016.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures rise modestly Thursday after Donald Trump's tax plan fails to deliver any surprises but instead raises many more questions.

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Market Recon: The Tax Reform Is Just Ordinary Negotiation on Steroids

Nobody shows their hand in negotiations. Why should government? This new tax plan must go to Congress.

Tax Reform Could Boost U.S. Businesses: Cramer's 'Mad Money' Recap (Wednesday 4/26/17)

Tax Reform Could Boost U.S. Businesses: Cramer's 'Mad Money' Recap (Wednesday 4/26/17)

True driving force behind this market remains earnings, says Jim Cramer, but don't ignore the impact of tax reform -- if it happens.

Chart of the Day: Celgene

This stock is poised for more upside.

Intermediate Trade: Celgene

Intermediate Trade: Celgene

I prefer a very short-term, out-of-the-money vertical call spread expiring in May.

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector

The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

Momentum Is Fading

Momentum Is Fading

Forget financials, stick to steady growers.